The effect of WIN 55,212-2 suggests a cannabinoid-sensitive component in the early toxicity induced by organic acids accumulating in glutaric acidemia type I and in related disorders of propionate metabolism in rat brain synaptosomes

Neuroscience. 2015 Dec 3:310:578-88. doi: 10.1016/j.neuroscience.2015.09.043. Epub 2015 Sep 30.

Abstract

Several physiological processes in the CNS are regulated by the endocannabinoid system (ECS). Cannabinoid receptors (CBr) and CBr agonists have been involved in the modulation of the N-methyl-D-aspartate receptor (NMDAr) activation. Glutaric (GA), 3-hydroxyglutaric (3-OHGA), methylmalonic (MMA) and propionic (PA) acids are endogenous metabolites produced and accumulated in the brain of children affected by severe organic acidemias (OAs) with neurodegeneration. Oxidative stress and excitotoxicity have been involved in the toxic pattern exerted by these organic acids. Studying the early pattern of toxicity exerted by these metabolites is crucial to explain the extent of damage that they can produce in the brain. Herein, we investigated the effects of the synthetic CBr agonist WIN 55,212-2 (WIN) on early markers of GA-, 3-OHGA-, MMA- and PA-induced toxicity in brain synaptosomes from adult (90-day-old) and adolescent (30-day-old) rats. As pre-treatment, WIN exerted protective effects on the GA- and MMA-induced mitochondrial dysfunction, and prevented the reactive oxygen species (ROS) formation and lipid peroxidation induced by all metabolites. Our findings support a protective and modulatory role of cannabinoids in the early toxic events elicited by toxic metabolites involved in OAs.

Keywords: endocannabinoid system; mitochondrial dysfunction; neuroprotection; organic acids; oxidative stress; synaptosomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acids, Acyclic / metabolism*
  • Acids, Acyclic / toxicity*
  • Amino Acid Metabolism, Inborn Errors / metabolism*
  • Animals
  • Benzoxazines / pharmacology*
  • Brain / drug effects
  • Brain / metabolism*
  • Brain Diseases, Metabolic / metabolism*
  • Cannabinoid Receptor Agonists / pharmacology*
  • Glutarates / metabolism
  • Glutarates / toxicity
  • Glutaryl-CoA Dehydrogenase / deficiency*
  • Glutaryl-CoA Dehydrogenase / metabolism
  • Lipid Peroxidation / drug effects
  • Male
  • Methylmalonic Acid / metabolism
  • Methylmalonic Acid / toxicity
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Morpholines / pharmacology*
  • Naphthalenes / pharmacology*
  • Oxidative Stress / drug effects*
  • Propionates / metabolism
  • Propionates / toxicity
  • Rats
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism

Substances

  • 3-hydroxyglutaric acid
  • Acids, Acyclic
  • Benzoxazines
  • Cannabinoid Receptor Agonists
  • Glutarates
  • Morpholines
  • Naphthalenes
  • Propionates
  • Reactive Oxygen Species
  • (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
  • Methylmalonic Acid
  • Glutaryl-CoA Dehydrogenase
  • glutaric acid
  • propionic acid

Supplementary concepts

  • Glutaric Acidemia I